Clinical trials: Ticagrelor
Coronary Artery Disease, Diabetes Mellitus
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
Patients with diabetes mellitus (DM) are at increased risk of atherothrombotic events. Importantly, DM is a key risk factor for the development of chronic kidney disease (CKD), which further enhances atherothrombotic risk.
- Trial name
- NCT02539160
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of Florida
Coronary Artery Disease, Atherosclerosis
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Stent Placement
- Trial name
- SYNIVUS-DAPT (NCT03606642)
- Testing
- Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- HonorHealth Research Institute
Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent
Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )
The aim of the Mashed Or Just Integral pill of TicagrelOr (MOJITO) study is to evaluate the superiority of Ticagrelor 180 mg LD mashed pill versus Ticagrelor 180 mg LD integral pill both orally administrated in decreasing…
- Trial name
- NCT01992523
- Testing
- Ticagrelor mashed pills, Ticagrelor integral pills
- Where
- 2 sites in Greece, Italy
- Volunteers
- 82 people
- Sponsor
- David Antoniucci
End Stage Renal Disease, Vascular Access Patency
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
This study is a randomized, placebo-controlled, single blind clinical trial. Seventy patients with ESRD on chronic HD and a functioning AVF will be recruited.
- Trial name
- NCT02335099
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Virginia
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Healthy
Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran
Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods
- Trial name
- NCT01595854
- Testing
- dabigatran etexilate, Ticagrelor
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor
To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran…
- Trial name
- NCT01734772
- Testing
- dabigatran etexilate, ticagrelor
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome
Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
This purpose of this study is to measure platelet response to ticagrelor and eptifibatide bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion administrated after cardiac catheterization in patients…
- Trial name
- NCT01919723
- Testing
- Ticagrelor, Eptifibatide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of Alabama at Birmingham
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
PROMUS Element Plus US Post-Approval Study
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
- Trial name
- NCT01589978
- Testing
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Where
- 52 sites in United States
- Volunteers
- 2,681 people
- Sponsor
- Boston Scientific Corporation
ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST…
- Trial name
- TASTER (NCT03822377)
- Testing
- Ticagrelor orodispersible tablets, Ticagrelor standard tablets
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero Universitaria di Sassari
Sickle Cell Disease
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
- Trial name
- HESTIA3 (NCT03615924)
- Testing
- Ticagrelor
- Where
- 55 sites in United States, Belgium and 14 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in African American Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
- Trial name
- NCT01523392
- Testing
- Ticagrelor, Clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Diabetes Mellitus, Coronary Artery Disease
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
Patients with diabetes mellitus (DM) have an increased risk of adverse atherothrombotic events. This may be in part attributed to the fact that these patients have reduced response to oral antiplatelet medications, in particular…
- Trial name
- NCT01852214
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Coronary Artery Disease
Efficacy and Safety of Low-dose Ticagrelor
Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients.
- Trial name
- NCT03381742
- Testing
- Ticagrelor, clopidogrel
- Where
- China
- Volunteers
- 3,043 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Peripheral Arterial Disease
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
This is a single center, prospective, randomized, unblinded, open-label, active controlled pilot study to evaluate the efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin in patients with Rutherford…
- Trial name
- NCT02230527
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- The Cleveland Clinic
Cardiac Arrest, Postresuscitation Syndrome
Antiplatelet Therapy After Cardiac Arrest
There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after cardiac arrest as in normothermic patients.
- Conditions
- Cardiac Arrest, Postresuscitation Syndrome, Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
- Trial name
- NCT02224274
- Testing
- Clopidogrel, Ticagrelor
- Where
- Slovenia
- Volunteers
- 57 people
- Sponsor
- University Medical Centre Ljubljana